The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
A Research Agenda for Malaria Eradication: Vaccines
Open accessAbstract
Vaccines could be a crucial component of efforts to eradicate malaria. Current attempts to develop malaria vaccines are primarily focused on Plasmodium falciparum and are directed towards reducing morbidity and mortality. Continued support for these efforts is essential, but if malaria vaccines are to be used as part of a repertoire of tools for elimination or eradication of malaria, they will need to have an impact on malaria transmission. We introduce the concept of "vaccines that interrupt malaria transmission" (VIMT), which includes not only "classical" transmission-blocking vaccines that target the sexual and mosquito stages but also pre-erythrocytic and asexual stage vaccines that have an effect on transmission. VIMT may also include vaccines that target the vector to disrupt parasite development in the mosquito. Importantly, if eradication is to be achieved, malaria vaccine development efforts will need to target other malaria parasite species, especially Plasmodium vivax, where novel therapeutic vaccines against hypnozoites or preventive vaccines with effect against multiple stages could have enormous impact. A target product profile (TPP) for VIMT is proposed and a research agenda to address current knowledge gaps and develop tools necessary for design and development of VIMT is presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The neglected burden of Plasmodium vivax malaria
Mendis, K., Sina, B., Marchesini, P., & Carter, R. (2001) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2001.64.97 · Cited by 970
Plasmodium knowlesi Malaria in Humans Is Widely Distributed and Potentially Life Threatening
Cox-Singh, J., Davis, T. M. E., Lee, K.-S., Shamsul, S. S. G., Matusop, A., Ratnam, S., Rahman, H. A., Conway, D. J., & Singh, B. (2008) · Clinical Infectious Diseases · doi:10.1086/524888 · Cited by 886
Vivax Malaria: Neglected and Not Benign
Price, R. N., Tjitra, E., Guerra, C. A., Yeung, S., White, N. J., & Anstey, N. M. (2007) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2007.77.79 · Cited by 838
Alonso, P. L., Sacarlal, J., Aponte, J. J., Leach, A., Macete, E., Milman, J., Mandomando, I., Spiessens, B., Guinovart, C., Espasa, M., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17223-1 · Cited by 752
TRAP Is Necessary for Gliding Motility and Infectivity of Plasmodium Sporozoites
Sultan, A. A., Thathy, V., Frevert, U., Robson, K. J. H., Crisanti, A., Nussenzweig, V., Nussenzweig, R. S., & Ménard, R. (1997) · Cell · doi:10.1016/s0092-8674(00)80511-5 · Cited by 651
Receptor and Ligand Domains for Invasion of Erythrocytes by Plasmodium falciparum
Sim, B. K. L., Chitnis, C. E., Wasniowska, K., Hadley, T. J., & Miller, L. H. (1994) · Science · doi:10.1126/science.8009226 · Cited by 545
Wu, Y., Ellis, R. D., Shaffer, D., Fontes, E., Malkin, E. M., Mahanty, S., Fay, M. P., Narum, D., Rausch, K., Miles, A. P., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002636 · Cited by 449
Effect of a fall in malaria transmission on morbidity and mortality in Kilifi, Kenya
O'Meara, W. P., Bejon, P., Mwangi, T. W., Okiro, E. A., Peshu, N., Snow, R. W., Newton, C. R., & Marsh, K. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61655-4 · Cited by 446 · cited 1×
“converted to low-to-moderate intensity transmission settings (EIR ,10) [11,12].”
BackgroundChanges in malaria indices between 1999 and 2007 in The Gambia: a retrospective analysis
Ceesay, S. J., Casals-Pascual, C., Erskine, J., Anya, S. E., Duah, N. O., Fulford, A. J., Sesay, S. S., Abubakar, I., Dunyo, S., Sey, O., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61654-2 · Cited by 425
Alonso, P. L., Sacarlal, J., Aponte, J. J., Leach, A., Macete, E., Aide, P., Sigauque, B., Milman, J., Mandomando, I., Bassat, Q., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67669-6 · Cited by 412
Severe Plasmodium vivax Malaria: A Report on Serial Cases from Bikaner in Northwestern India
Kochar, D. K., Das, A., Kochar, S. K., Saxena, V., Sirohi, P., Garg, S., Kochar, A., Khatri, M. P., & Gupta, V. (2009) · The American Journal of Tropical Medicine and Hygiene · doi:10.4269/ajtmh.2009.80.194 · Cited by 398
Kochar, D. K., Saxena, V., Singh, N., Kochar, S. K., Kumar, S. V., & Das, A. (2005) · Emerging Infectious Diseases · doi:10.3201/eid1101.040519 · Cited by 382
Cerami, C., Frevert, U., Sinnis, P., Takacs, B., Clavijo, P., Santos, M. J., & Nussenzweig, V. (1992) · Cell · doi:10.1016/0092-8674(92)90251-7 · Cited by 356
New developments in Plasmodium vivax malaria: severe disease and the rise of chloroquine resistance
Price, R. N., Douglas, N. M., & Anstey, N. M. (2009) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0b013e32832f14c1 · Cited by 343
Roper, M. H., Vandelaer, J. H., & Gasse, F. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61261-6 · Cited by 310
Hoffman, S. L., Billingsley, P. F., James, E., Richman, A., Loyevsky, M., Li, T., Chakravarty, S., Gunasekera, A., Chattopadhyay, R., Li, M., et al. (2010) · Human Vaccines · doi:10.4161/hv.6.1.10396 · Cited by 297
A Research Agenda for Malaria Eradication: Drugs
The malERA Consultative Group on Drugs (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000402 · Cited by 288
Adegbola, R. A., Secka, O., Lahai, G., Lloyd-Evans, N., Njie, A., Usen, S., Oluwalana, C., Obaro, S., Weber, M., Corrah, T., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66788-8 · Cited by 286 · cited 1×
“Vaccines have also been useful for sustained control of diseases such as neonatal tetanus [5], and vaccines such as Haemophilus influenzae type b conjugate vaccine have the potential to lead to elimination in some settings [6].”
BackgroundA Research Agenda for Malaria Eradication: Vector Control
The malERA Consultative Group on Vector Control (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000401 · Cited by 273
A Research Agenda for Malaria Eradication: Diagnoses and Diagnostics
The malERA Consultative Group on Diagnoses and Diagnostics (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000396 · Cited by 248
Moss, W. J., & Griffin, D. E. (2006) · Nature Reviews Microbiology · doi:10.1038/nrmicro1550 · Cited by 247
Phase 1 vaccine trial of Pvs25H: a transmission blocking vaccine for Plasmodium vivax malaria
Malkin, E. M., Durbin, A. P., Diemert, D. J., Sattabongkot, J., Wu, Y., Miura, K., Long, C. A., Lambert, L., Miles, A. P., Wang, J., et al. (2005) · Vaccine · doi:10.1016/j.vaccine.2004.12.019 · Cited by 239
Moderate Effect of Artemisinin‐Based Combination Therapy on Transmission of Plasmodium falciparum
Bousema, J. T., Schneider, P., Gouagna, L. C., Drakeley, C. J., Tostmann, A., Houben, R., Githure, J. I., Ord, R., Sutherland, C. J., Omar, S. A., et al. (2006) · The Journal of Infectious Diseases · doi:10.1086/503051 · Cited by 208
Transmission blocking malaria vaccines
Carter, R. (2001) · Vaccine · doi:10.1016/s0264-410x(00)00521-1 · Cited by 201
Dinglasan, R. R., Kalume, D. E., Kanzok, S. M., Ghosh, A. K., Muratova, O., Pandey, A., & Jacobs-Lorena, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702239104 · Cited by 187
Grimberg, B. T., Udomsangpetch, R., Xainli, J., McHenry, A., Panichakul, T., Sattabongkot, J., Cui, L., Bockarie, M., Chitnis, C., Adams, J., et al. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040337 · Cited by 184
A Research Agenda for Malaria Eradication: Monitoring, Evaluation, and Surveillance
The malERA Consultative Group on Monitoring, E. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000400 · Cited by 161
Outchkourov, N. S., Roeffen, W., Kaan, A., Jansen, J., Luty, A. J. F., Schuiffel, D., van Gemert, G. J., van de Vegte‐Bolmer, M., Sauerwein, R. W., & Stunnenberg, H. G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800459105 · Cited by 147
DDT house spraying and re-emerging malaria
Roberts, D., Manguin, S., & Mouchet, J. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02516-2 · Cited by 143
Chowdhury, D. R., Angov, E., Kariuki, T., & Kumar, N. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006352 · Cited by 124
Pandey, K. C. (2002) · Molecular and Biochemical Parasitology · doi:10.1016/s0166-6851(02)00122-6 · Cited by 117
A Research Agenda for Malaria Eradication: Modeling
The malERA Consultative Group on Modeling (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000403 · Cited by 105
A Research Agenda for Malaria Eradication: Basic Science and Enabling Technologies
The malERA Consultative Group on Basic Science and Enabling Technologies (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000399 · Cited by 102
Principles and lessons from the smallpox eradication programme.
Henderson, D. A. (1987) · PubMed · Cited by 94
Lee, K.-S., Cox‐Singh, J., Brooke, G., Matusop, A., & Singh, B. B. (2009) · International Journal for Parasitology · doi:10.1016/j.ijpara.2009.03.003 · Cited by 93
van der Kolk, M., de Vlas, S. J., Saul, A. J., VEGTE-BOLMER, M. V. D., ELING, W., & SAUERWEIN, W. (2004) · Parasitology · doi:10.1017/s0031182004006067 · Cited by 92
Kochar, D. K., Das, A., Kochar, A., Middha, S., Acharya, J., Tanwar, G. S., Gupta, A., Pakalapati, D., Garg, S., Saxena, V., et al. (2010) · Platelets · doi:10.3109/09537104.2010.505308 · Cited by 91
Sex in Plasmodium: a sign of commitment
Dixon, M. W. A., Thompson, J., Gardiner, D. L., & Trenholme, K. R. (2008) · Trends in Parasitology · doi:10.1016/j.pt.2008.01.004 · Cited by 88
Narum, D. L., Haynes, J. D., Fuhrmann, S. R., et al. (2000) · Infection and Immunity · doi:10.1128/iai.68.4.1964-1966.2000 · Cited by 84
What Should Vaccine Developers Ask? Simulation of the Effectiveness of Malaria Vaccines
Penny, M. A., Maire, N., Studer, A., Schapira, A., & Smith, T. A. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003193 · Cited by 75
A Research Agenda for Malaria Eradication: Cross-Cutting Issues for Eradication
The malERA Consultative Group on Integration Strategies (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000404 · Cited by 37
Breman, J. G., de Quadrós, C. A., Dowdle, W. R., Foege, W. H., Henderson, D. A., John, T. J., & Levine, M. M. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000405 · Cited by 35
Pattnaik, P., Shakri, A. R., Singh, S., et al. (2006) · Vaccine · doi:10.1016/j.vaccine.2006.09.048 · Cited by 34
Role of injectable and oral polio vaccines in polio eradication
John, J. K. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.8.1.5 · Cited by 27
Cited by
Protection Against Malaria by Intravenous Immunization with a Nonreplicating Sporozoite Vaccine
Seder, R. A., Chang, L.-J., Enama, M. E., Zephir, K. L., Sarwar, U. N., Gordon, I. J., Holman, L. A., James, E. R., Billingsley, P. F., Gunasekera, A., et al. (2013) · Science · doi:10.1126/science.1241800 · Cited by 761
A Research Agenda to Underpin Malaria Eradication
Alonso, P. L., Brown, G., Arevalo-Herrera, M., Binka, F., Chitnis, C., Collins, F., Doumbo, O. K., Greenwood, B., Hall, B. F., Levine, M. M., et al. (2011) · PLoS Medicine · doi:10.1371/journal.pmed.1000406 · Cited by 667
Hitting Hotspots: Spatial Targeting of Malaria for Control and Elimination
Bousema, T., Griffin, J. T., Sauerwein, R. W., Smith, D. L., Churcher, T. S., Takken, W., Ghani, A., Drakeley, C., & Gosling, R. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001165 · Cited by 561
Live Attenuated Malaria Vaccine Designed to Protect Through Hepatic CD8 + T Cell Immunity
Epstein, J. E., Tewari, K., Lyke, K. E., Sim, B. K. L., Billingsley, P. F., Laurens, M. B., Gunasekera, A., Chakravarty, S., James, E. R., Sedegah, M., et al. (2011) · Science · doi:10.1126/science.1211548 · Cited by 533
Sterile protection against human malaria by chemoattenuated PfSPZ vaccine
Mordmüller, B., Surat, G., Lagler, H., Chakravarty, S., Ishizuka, A. S., Lalremruata, A., Gmeiner, M., Campo, J. J., Esen, M., Ruben, A. J., et al. (2017) · Nature · doi:10.1038/nature21060 · Cited by 403
Metadata
- Authors
- The malERA Consultative Group on Vaccines
- Venue
- PLoS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-01-25
- Volume
- 8
- Issue
- 1
- Pages
- e1000398
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W1527871699
- Cited by
- 264
- References
- 44
- FWCI
- 31.46
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.